desvenlafaxine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4380 93413-62-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • desvenlafaxine
  • desvenlafaxine succinate
  • pristiq
  • DVS-233
  • desvenlafaxine fumarate
The exact mechanism of the antidepressant action of desvenlafaxine is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Non-clinical studies have shown that desvenlafaxine is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI).
  • Molecular weight: 263.38
  • Formula: C16H25NO2
  • CLOGP: 2.68
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 2
  • TPSA: 43.70
  • ALOGS: -2.27
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 572 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 45 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 5.42 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 3.50 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.70 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 8.40 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 0.047 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.966 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 7.499 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 4.406 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 82.080 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 86.240 % High 1
herg hERG pIC50 4.403 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.033 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.013 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 87.220 % High 1
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAP2K6,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK2,PDK4,PRKDC,TEK,TGFBR1,ZAP70 26
kinase-selectivity-class EIF2AK3,GRK2 2
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 2.864 Moderate 0.72
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.503 High 1
mh-clint Mouse hepatocyte intrinsic clearance 18.197 High 1
mppb Mouse plasma protein binding (% unbound) 84.180 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 4.688 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 High 1
pppb Pig plasma protein binding (% unbound) 83.680 % High 1
rat-kpuu-brain Rat brain Kpuu 0.157 % Moderate 0.72
rh-clint Rat hepatocyte intrinsic clearance 36.058 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 88.770 % High 1
rppb Rat plasma protein binding (% unbound) 85.510 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 952.796 uM High 1

Approvals:

DateAgencyCompanyOrphan
Feb. 29, 2008 FDA WYETH PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product residue present 821.38 14.73 203 27662 4088 90596494
Drug withdrawal syndrome 704.91 14.73 282 27583 28441 90572141
Suicidal ideation 452.33 14.73 282 27583 73573 90527009
Feeling abnormal 334.45 14.73 329 27536 166906 90433676
Withdrawal syndrome 318.61 14.73 150 27715 22374 90578208
Crying 297.15 14.73 149 27716 25496 90575086
Anxiety 248.12 14.73 384 27481 309388 90291194
Irritability 230.39 14.73 141 27724 35521 90565061
Insomnia 175.99 14.73 344 27521 333130 90267452
Dizziness 169.47 14.73 479 27386 588805 90011777
Anger 165.64 14.73 82 27783 13638 90586944
Nausea 145.65 14.73 699 27166 1109617 89490965
Completed suicide 145.15 14.73 200 27665 144858 90455724
Dissociation 144.29 14.73 60 27805 6655 90593927
Hyperhidrosis 136.47 14.73 188 27677 136117 90464465
Panic attack 122.96 14.73 85 27780 26280 90574302
Nervousness 120.70 14.73 93 27772 33963 90566619
Agitation 119.22 14.73 124 27741 66974 90533608
Headache 116.32 14.73 548 27317 862198 89738384
Tremor 115.55 14.73 185 27680 152988 90447594
Depression 102.89 14.73 261 27604 300340 90300242
Abnormal dreams 97.87 14.73 54 27811 11203 90589379
Emotional disorder 93.52 14.73 58 27807 14939 90585643
Serotonin syndrome 87.81 14.73 81 27784 37806 90562776
Synovitis 81.51 14.73 5 27860 329747 90270835
Suicide attempt 81.50 14.73 108 27757 75291 90525291
Feeling jittery 77.47 14.73 52 27813 15319 90585263
Systemic lupus erythematosus 77.36 14.73 10 27855 361886 90238696
Nightmare 76.26 14.73 59 27806 21666 90578916
Thinking abnormal 74.74 14.73 46 27819 11686 90588896
Intentional product misuse 74.17 14.73 113 27752 89491 90511091
Condition aggravated 70.49 14.73 365 27500 595180 90005402
Pericarditis 70.21 14.73 3 27862 270148 90330434
Stomatitis 68.38 14.73 4 27861 274694 90325888
Contraindicated product administered 68.05 14.73 9 27856 320130 90280452
Drug ineffective 64.94 14.73 679 27186 1383619 89216963
Vision blurred 64.43 14.73 119 27746 110174 90490408
Somnolence 62.76 14.73 173 27692 208911 90391671
Overdose 62.49 14.73 145 27720 157564 90443018
Disturbance in attention 61.24 14.73 74 27791 47035 90553547
General physical health deterioration 60.72 14.73 17 27848 355098 90245484
Product substitution issue 59.09 14.73 47 27818 17961 90582621
Seizure 59.02 14.73 139 27726 152490 90448092
Depressed mood 55.90 14.73 73 27792 50149 90550433
Joint swelling 55.63 14.73 44 27821 503256 90097326
Infusion related reaction 54.76 14.73 30 27835 416750 90183832
Pre-existing condition improved 53.49 14.73 34 27831 9135 90591447
Lower respiratory tract infection 53.37 14.73 7 27858 250652 90349930
Mood altered 52.55 14.73 43 27822 17101 90583481
Blood pressure increased 52.21 14.73 156 27709 197061 90403521
Mania 50.97 14.73 39 27826 14085 90586497
Wound 50.87 14.73 15 27850 302965 90297617
Pyrexia 50.72 14.73 78 27787 660407 89940175
Arthropathy 50.12 14.73 25 27840 366217 90234365
Persistent genital arousal disorder 48.88 14.73 15 27850 685 90599897
Mydriasis 48.87 14.73 39 27826 14973 90585609
Glossodynia 48.70 14.73 19 27846 321760 90278822
Maternal exposure during pregnancy 48.64 14.73 25 27840 360038 90240544
Drug screen positive 46.96 14.73 23 27842 3734 90596848
Tinnitus 46.96 14.73 62 27803 43040 90557542
Impaired healing 46.50 14.73 8 27857 234191 90366391
Impaired driving ability 45.47 14.73 25 27840 5148 90595434
Therapeutic response unexpected 45.39 14.73 44 27821 21836 90578746
Middle insomnia 45.13 14.73 39 27826 16712 90583870
Sedation 44.52 14.73 64 27801 48107 90552475
C-reactive protein increased 44.05 14.73 3 27862 181386 90419196
Peripheral swelling 43.30 14.73 38 27827 413068 90187514
Aggression 41.56 14.73 46 27819 26622 90573960
Treatment failure 41.19 14.73 21 27844 303907 90296675
Rheumatoid arthritis 40.93 14.73 31 27834 362583 90237999
Coma scale abnormal 40.86 14.73 24 27841 5602 90594980
Drug screen false positive 40.57 14.73 14 27851 929 90599653
Anorgasmia 40.53 14.73 13 27852 687 90599895
Abnormal behaviour 40.49 14.73 42 27823 22586 90577996
Wrong technique in product usage process 40.26 14.73 76 27789 71495 90529087
Hepatic enzyme increased 39.25 14.73 32 27833 360704 90239878
Tachyphrenia 39.21 14.73 16 27849 1690 90598892
Energy increased 38.64 14.73 19 27846 3111 90597471
Bruxism 38.11 14.73 21 27844 4342 90596240
Restlessness 36.80 14.73 50 27815 35670 90564912
Euphoric mood 36.48 14.73 22 27843 5387 90595195
Infection 35.94 14.73 35 27830 362059 90238523
Tardive dyskinesia 34.73 14.73 28 27837 10902 90589680
Paranoia 34.66 14.73 30 27835 12878 90587704
Yawning 34.64 14.73 13 27852 1099 90599483
Swelling 34.57 14.73 47 27818 419011 90181571
Mental disorder 34.45 14.73 46 27819 32272 90568310
Type 2 diabetes mellitus 34.22 14.73 10 27855 203234 90397348
Abdominal discomfort 33.23 14.73 60 27805 477268 90123314
Palpitations 33.22 14.73 105 27760 136623 90463959
Acute kidney injury 32.92 14.73 30 27835 320357 90280225
Mood swings 32.76 14.73 36 27829 20666 90579916
Stress 32.39 14.73 75 27790 81320 90519262
Unevaluable event 31.79 14.73 59 27806 54789 90545793
Nonspecific reaction 31.57 14.73 16 27849 2793 90597789
Ill-defined disorder 31.30 14.73 9 27856 184882 90415700
Paraesthesia 30.59 14.73 155 27710 250171 90350411
Thrombocytopenia 30.47 14.73 13 27852 208712 90391870
Blister 29.80 14.73 21 27844 254977 90345605
Bursitis 29.70 14.73 3 27862 131651 90468931
Post-traumatic stress disorder 29.47 14.73 21 27844 6807 90593775
Wheezing 28.63 14.73 19 27846 238061 90362521
Lung disorder 27.88 14.73 6 27859 149877 90450705
Libido decreased 27.84 14.73 15 27850 2967 90597615
Bipolar disorder 26.42 14.73 22 27843 8963 90591619
Apathy 26.34 14.73 24 27841 11016 90589566
Mobility decreased 26.33 14.73 23 27842 250711 90349871
Panic reaction 26.30 14.73 17 27848 4700 90595882
Hypersensitivity vasculitis 25.71 14.73 16 27849 4143 90596439
Hostility 25.70 14.73 13 27852 2260 90598322
Discomfort 25.53 14.73 28 27837 274307 90326275
Hallucination 25.39 14.73 60 27805 65899 90534683
Loss of libido 25.33 14.73 11 27854 1356 90599226
Obsessive-compulsive disorder 24.54 14.73 16 27849 4488 90596094
Neutropenia 24.38 14.73 20 27845 224884 90375698
Alopecia 24.24 14.73 75 27790 494996 90105586
Pancytopenia 24.10 14.73 4 27861 120259 90480323
Galactorrhoea 24.01 14.73 16 27849 4656 90595926
Product administration interrupted 23.83 14.73 24 27841 12468 90588114
Tearfulness 23.67 14.73 16 27849 4764 90595818
Muscle twitching 23.61 14.73 33 27832 24169 90576413
Vertigo 23.17 14.73 60 27805 69751 90530831
Product dose omission issue 22.98 14.73 161 27704 291526 90309056
Suicidal behaviour 22.97 14.73 13 27852 2831 90597751
Sympathomimetic effect 22.95 14.73 6 27859 152 90600430
Oedema 22.74 14.73 17 27848 200278 90400304
Musculoskeletal stiffness 22.72 14.73 35 27830 296497 90304085
Malabsorption 22.52 14.73 16 27849 5162 90595420
Drug intolerance 22.48 14.73 67 27798 447524 90153058
Therapeutic response changed 22.47 14.73 10 27855 1307 90599275
Death 22.46 14.73 69 27796 456482 90144100
Hallucination, auditory 22.25 14.73 26 27839 15949 90584633
Hypersomnia 21.96 14.73 30 27835 21501 90579081
Drug dependence 21.50 14.73 35 27830 29292 90571290
Increased appetite 21.34 14.73 22 27843 11743 90588839
Drug hypersensitivity 21.30 14.73 227 27638 463382 90137200
Mental impairment 21.29 14.73 26 27839 16694 90583888
Migraine 21.25 14.73 115 27750 190277 90410305
Restless legs syndrome 20.97 14.73 30 27835 22440 90578142
Negative thoughts 20.90 14.73 9 27856 1088 90599494
Brain injury 20.81 14.73 18 27847 7720 90592862
Electric shock sensation 20.79 14.73 10 27855 1560 90599022
Heart rate increased 20.71 14.73 79 27786 112823 90487759
Pulmonary fibrosis 20.62 14.73 4 27861 107499 90493083
Major depression 20.47 14.73 20 27845 10015 90590567
Toxicity to various agents 20.44 14.73 155 27710 287691 90312891
Weight increased 19.83 14.73 206 27659 417721 90182861
Psoriatic arthropathy 19.43 14.73 25 27840 228310 90372272
Pneumonia 19.35 14.73 116 27749 637943 89962639
Drug interaction 19.15 14.73 148 27717 276305 90324277
Feeling drunk 19.09 14.73 14 27851 4744 90595838
Grip strength decreased 18.73 14.73 3 27862 92573 90508009
Breast tenderness 18.59 14.73 11 27854 2601 90597981
Surgery 18.56 14.73 42 27823 44845 90555737
Blood triglycerides increased 18.51 14.73 22 27843 13739 90586843
Sleep-related eating disorder 18.35 14.73 8 27857 996 90599586
Impaired work ability 18.33 14.73 26 27839 19300 90581282
Product prescribing error 18.19 14.73 33 27832 30112 90570470
Hypersensitivity 18.17 14.73 75 27790 454602 90145980
Regurgitation 17.76 14.73 10 27855 2156 90598426
Anaemia 17.57 14.73 53 27812 352749 90247833
Hypertensive emergency 17.54 14.73 10 27855 2207 90598375
Febrile neutropenia 17.26 14.73 14 27851 158335 90442247
Intestinal pseudo-obstruction 17.22 14.73 8 27857 1155 90599427
Inflammation 16.86 14.73 18 27847 178574 90422008
Wernicke-Korsakoff syndrome 16.70 14.73 4 27861 70 90600512
Impatience 16.69 14.73 6 27859 449 90600133
Lower limb fracture 16.65 14.73 3 27862 85010 90515572
Hot flush 16.62 14.73 48 27817 59440 90541142
Wrong strength 16.44 14.73 4 27861 75 90600507
Attention deficit hyperactivity disorder 16.09 14.73 12 27853 4172 90596410
Emotional distress 15.94 14.73 35 27830 36627 90563955
Nasopharyngitis 15.74 14.73 68 27797 407036 90193546
Disease progression 15.68 14.73 15 27850 156600 90443982
Illness 15.57 14.73 58 27807 81911 90518671
Decreased interest 15.53 14.73 12 27853 4395 90596187
Hyperacusis 15.35 14.73 10 27855 2801 90597781
Sciatica 15.30 14.73 6 27859 101376 90499206
Fear 15.23 14.73 22 27843 16600 90583982
Normetanephrine urine increased 15.16 14.73 3 27862 20 90600562
Change in seizure presentation 15.16 14.73 6 27859 586 90599996
Live birth 15.05 14.73 3 27862 79104 90521478
Wound infection 14.93 14.73 7 27858 106395 90494187
Dyskinesia 14.90 14.73 34 27831 36500 90564082

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product residue present 230.21 21.89 61 7766 2780 42610728
Drug withdrawal syndrome 183.17 21.89 86 7741 21463 42592045
Serotonin syndrome 180.04 21.89 90 7737 25755 42587753
Suicidal ideation 132.75 21.89 92 7735 48069 42565439
Anxiety 105.50 21.89 119 7708 118441 42495067
Dissociation 83.60 21.89 30 7797 3768 42609740
Suicide attempt 70.10 21.89 62 7765 46038 42567470
Overdose 69.64 21.89 91 7736 105173 42508335
Completed suicide 69.48 21.89 87 7740 96378 42517130
Hyperhidrosis 67.38 21.89 83 7744 90429 42523079
Sexual dysfunction 57.38 21.89 27 7800 6748 42606760
Insomnia 57.14 21.89 88 7739 118165 42495343
Feeling abnormal 56.82 21.89 67 7760 69719 42543789
Major depression 53.51 21.89 24 7803 5374 42608134
Depression 51.18 21.89 81 7746 111282 42502226
Withdrawal syndrome 49.73 21.89 32 7795 14743 42598765
Sedation 46.33 21.89 41 7786 30434 42583074
Anger 45.81 21.89 29 7798 12989 42600519
Panic attack 42.39 21.89 26 7801 11019 42602489
Schizophreniform disorder 42.22 21.89 8 7819 74 42613434
Nervousness 39.93 21.89 27 7800 13505 42600003
Drug interaction 39.51 21.89 123 7704 266876 42346632
Thinking abnormal 38.52 21.89 21 7806 7140 42606368
Dizziness 36.10 21.89 114 7713 249140 42364368
Drug ineffective 33.91 21.89 214 7613 629983 41983525
Tremor 33.30 21.89 62 7765 96867 42516641
Crying 32.33 21.89 18 7809 6376 42607132
Coma scale abnormal 32.04 21.89 16 7811 4549 42608959
Erectile dysfunction 31.03 21.89 30 7797 24883 42588625
Mania 31.01 21.89 21 7806 10526 42602982
Irritability 27.98 21.89 30 7797 28098 42585410
Drug screen positive 27.58 21.89 14 7813 4117 42609391
Libido decreased 27.56 21.89 15 7812 5083 42608425
Homicide 27 21.89 9 7818 906 42612602
Headache 26.35 21.89 100 7727 239269 42374239
Toxic encephalopathy 25.74 21.89 16 7811 6937 42606571
Paralysis 25.60 21.89 16 7811 7004 42606504
Emotional disorder 24.57 21.89 15 7812 6299 42607209
Glycogen storage disorder 24.40 21.89 4 7823 14 42613494
Abnormal behaviour 24.20 21.89 27 7800 26424 42587084
Drug screen false positive 23.19 21.89 8 7819 894 42612614
Bipolar disorder 22.49 21.89 12 7815 3910 42609598
Acute kidney injury 22.09 21.89 21 7806 367316 42246192
Ejaculation disorder 22.02 21.89 8 7819 1040 42612468

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Suicidal ideation 289.01 14.35 206 24128 93731 110471234
Withdrawal syndrome 279.58 14.35 137 24197 31243 110533722
Drug withdrawal syndrome 249.03 14.35 135 24199 37919 110527046
Feeling abnormal 239.29 14.35 244 24090 180467 110384498
Dissociation 232.93 14.35 86 24248 9756 110555209
Serotonin syndrome 215.49 14.35 144 24190 59009 110505956
Product residue present 199.40 14.35 61 24273 3880 110561085
Completed suicide 198.17 14.35 255 24079 242126 110322839
Crying 196.25 14.35 101 24233 25527 110539438
Anxiety 183.65 14.35 296 24038 344782 110220183
Overdose 143.04 14.35 214 24120 233580 110331385
Irritability 138.14 14.35 101 24233 47708 110517257
Anger 120.34 14.35 66 24268 18941 110546024
Suicide attempt 117.83 14.35 129 24205 103265 110461700
Depression 98.19 14.35 216 24118 317119 110247846
Panic attack 97.12 14.35 67 24267 28873 110536092
Dizziness 94.28 14.35 352 23982 697841 109867124
Hyperhidrosis 91.80 14.35 155 24179 187143 110377822
Insomnia 81.06 14.35 217 24117 360373 110204592
Nervousness 80.56 14.35 66 24268 36785 110528180
Emotional disorder 75.36 14.35 46 24288 16114 110548851
Tremor 74.58 14.35 148 24186 202084 110362881
Sedation 72.60 14.35 83 24251 69600 110495365
Coma scale abnormal 70.62 14.35 37 24297 9689 110555276
Product substitution issue 69.51 14.35 50 24284 23011 110541954
Headache 66.68 14.35 375 23959 882002 109682963
Nausea 63.32 14.35 476 23858 1235214 109329751
Major depression 62.09 14.35 35 24299 10586 110554379
Drug ineffective 61.48 14.35 555 23779 1519985 109044980
Thinking abnormal 60.30 14.35 39 24295 15101 110549864
Depressed mood 55.99 14.35 68 24266 60741 110504224
Persistent genital arousal disorder 54.36 14.35 15 24319 661 110564304
Abnormal dreams 53.58 14.35 34 24300 12746 110552219
Agitation 51.99 14.35 91 24243 112960 110452005
General physical health deterioration 51.25 14.35 15 24319 425280 110139685
Toxicity to various agents 49.42 14.35 223 24111 480332 110084633
Pre-existing condition improved 47.87 14.35 25 24309 6501 110558464
Acute kidney injury 47.50 14.35 42 24292 635388 109929577
Intentional product misuse 46.26 14.35 95 24239 132809 110432156
Tardive dyskinesia 44.53 14.35 31 24303 13548 110551417
Synovitis 42.92 14.35 5 24329 274087 110290878
Drug interaction 42.68 14.35 220 24114 499963 110065002
Mood altered 41.99 14.35 36 24298 21339 110543626
Nightmare 39.98 14.35 46 24288 38817 110526148
Drug hypersensitivity 38.92 14.35 200 24134 453890 110111075
Seizure 38.90 14.35 122 24212 221063 110343902
Therapeutic response unexpected 38.60 14.35 36 24298 23807 110541158
Product dose omission issue 38.18 14.35 156 24178 321626 110243339
Impaired driving ability 37.25 14.35 21 24313 6349 110558616
Mania 36.79 14.35 33 24301 20763 110544202
Mental disorder 36.72 14.35 44 24290 38747 110526218
Feeling jittery 35.64 14.35 28 24306 14694 110550271
Pancytopenia 34.96 14.35 3 24331 209610 110355355
Febrile neutropenia 34.94 14.35 13 24321 316754 110248211
Schizophreniform disorder 34.20 14.35 8 24326 179 110564786
Pyrexia 34.01 14.35 94 24240 898171 109666794
Disturbance in attention 33.97 14.35 54 24280 61941 110503024
Stomatitis 33.52 14.35 9 24325 270233 110294732
Panic reaction 32.36 14.35 18 24316 5304 110559661
Vision blurred 31.32 14.35 80 24254 128942 110436023
Paranoia 30.98 14.35 31 24303 22343 110542622
Lower respiratory tract infection 30.34 14.35 8 24326 243098 110321867
Neutropenia 30.15 14.35 23 24311 374597 110190368
Abnormal behaviour 30.14 14.35 40 24294 38999 110525966
Helicobacter infection 29.28 14.35 3 24331 181874 110383091
Mood swings 28.67 14.35 30 24304 22782 110542183
Thrombocytopenia 28.61 14.35 21 24313 348864 110216101
Bipolar disorder 28.22 14.35 20 24314 8987 110555978
Tinnitus 28.17 14.35 49 24285 60491 110504474
Intentional overdose 27.96 14.35 78 24256 132423 110432542
Hostility 27.73 14.35 13 24321 2683 110562282
Contraindicated product administered 26.04 14.35 11 24323 248256 110316709
Pericarditis 25.88 14.35 8 24326 219106 110345859
Product prescribing error 25.80 14.35 43 24291 51288 110513677
Joint swelling 25.67 14.35 36 24298 442809 110122156
Impaired healing 25.46 14.35 6 24328 196711 110368254
Drug dependence 25.27 14.35 42 24292 49978 110514987
Hypersomnia 25.21 14.35 31 24303 28030 110536935
Product dispensing error 25.16 14.35 24 24310 16321 110548644
Aggression 25.08 14.35 46 24288 59164 110505801
Suicidal behaviour 24.52 14.35 13 24321 3484 110561481
Product administration interrupted 24.20 14.35 20 24314 11272 110553693
Yawning 24.14 14.35 10 24324 1537 110563428
Infusion related reaction 24.14 14.35 29 24305 381133 110183832
C-reactive protein increased 23.93 14.35 9 24325 217910 110347055
Glycogen storage disorder 23.68 14.35 4 24330 14 110564951
Wound 23.62 14.35 11 24323 234426 110330539
Somnolence 23.39 14.35 128 24206 297321 110267644
Multiple organ dysfunction syndrome 23.17 14.35 3 24331 151707 110413258
Hypersensitivity vasculitis 23.13 14.35 16 24318 6921 110558044
Tachyphrenia 23.12 14.35 11 24323 2345 110562620
Hepatic enzyme increased 23.00 14.35 22 24312 320870 110244095
Liver injury 22.91 14.35 3 24331 150410 110414555
Bruxism 22.73 14.35 14 24320 4980 110559985
Frustration tolerance decreased 21.99 14.35 17 24317 8714 110556251
Mental impairment 21.95 14.35 26 24308 22613 110542352
Drug screen positive 21.88 14.35 15 24319 6395 110558570
Euphoric mood 21.83 14.35 17 24317 8810 110556155
Malignant neoplasm progression 21.29 14.35 6 24328 174561 110390404
Reversible cerebral vasoconstriction syndrome 20.79 14.35 13 24321 4748 110560217
Muscle twitching 20.58 14.35 29 24305 29906 110535059
Lung disorder 20.51 14.35 7 24327 180040 110384925
Emotional distress 20.47 14.35 36 24298 44811 110520154
Therapeutic response changed 20.43 14.35 9 24325 1609 110563356
Condition aggravated 20.36 14.35 249 24085 734587 109830378
Arthropathy 20.27 14.35 20 24314 287502 110277463
Obsessive-compulsive disorder 20.23 14.35 15 24319 7226 110557739
Vertigo 20.19 14.35 53 24281 86817 110478148
Anaemia 20.11 14.35 58 24276 547028 110017937
Type 2 diabetes mellitus 20.00 14.35 7 24327 177225 110387740
Illness 19.99 14.35 51 24283 82120 110482845
Impulsive behaviour 19.58 14.35 11 24323 3304 110561661
Peripheral swelling 19.52 14.35 37 24297 403997 110160968
Palpitations 19.50 14.35 78 24256 159134 110405831
Infection 19.48 14.35 31 24303 362169 110202796
Stress 19.33 14.35 59 24275 105289 110459676
Self-injurious ideation 19.31 14.35 12 24322 4334 110560631
Sympathomimetic effect 19.20 14.35 5 24329 176 110564789
Mydriasis 19.14 14.35 24 24310 22133 110542832
Blood pressure increased 18.86 14.35 109 24225 258264 110306701
Electric shock sensation 18.85 14.35 9 24325 1935 110563030
Surgery 18.67 14.35 33 24301 41250 110523715
Energy increased 18.53 14.35 11 24323 3663 110561302
False positive investigation result 18.29 14.35 8 24326 1406 110563559
Renal failure 18.10 14.35 14 24320 226560 110338405
Wrong technique in product usage process 18.01 14.35 51 24283 87297 110477668
Wernicke-Korsakoff syndrome 17.93 14.35 4 24330 72 110564893
Wrong strength 17.87 14.35 5 24329 232 110564733
Blunted affect 17.59 14.35 6 24328 540 110564425
Ankyloglossia congenital 17.44 14.35 3 24331 12 110564953
Affect lability 17.41 14.35 21 24313 18616 110546349
Ejaculation disorder 17.19 14.35 6 24328 578 110564387
Post-traumatic stress disorder 16.96 14.35 13 24321 6583 110558382
Blood pressure orthostatic 16.96 14.35 4 24330 93 110564872
Hypertensive emergency 16.81 14.35 10 24324 3341 110561624
Rheumatoid arthritis 16.72 14.35 25 24309 299588 110265377
Septic shock 16.48 14.35 7 24327 157521 110407444
Breast tenderness 16.25 14.35 9 24325 2631 110562334
Glossodynia 16.16 14.35 15 24319 221989 110342976
Hallucination 16.05 14.35 54 24280 101378 110463587
Disease progression 16.05 14.35 18 24316 244016 110320949
Hyperkalaemia 15.95 14.35 5 24329 135791 110429174
Normetanephrine urine increased 15.91 14.35 3 24331 22 110564943
Renal impairment 15.89 14.35 11 24323 188434 110376531
Impaired work ability 15.85 14.35 24 24310 26395 110538570
Brain injury 15.66 14.35 17 24317 13459 110551506
Migraine 15.65 14.35 77 24257 171575 110393390
Wheezing 15.54 14.35 20 24314 255210 110309755
Maternal exposure during pregnancy 15.49 14.35 20 24314 254863 110310102
Drug screen false positive 15.32 14.35 7 24327 1362 110563603
Paralysis 15.26 14.35 18 24316 15582 110549383
Change in seizure presentation 15.11 14.35 6 24328 828 110564137
Dysphoria 15.08 14.35 12 24322 6416 110558549
Antidepressant discontinuation syndrome 15.04 14.35 4 24330 153 110564812
Drug effective for unapproved indication 14.96 14.35 17 24317 14150 110550815
Drug-induced liver injury 14.88 14.35 4 24330 120063 110444902
Blister 14.70 14.35 17 24317 227359 110337606
Swelling 14.57 14.35 35 24299 351006 110213959

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06AX23 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Other antidepressants
FDA MoA N0000000102 Norepinephrine Uptake Inhibitors
FDA MoA N0000000109 Serotonin Uptake Inhibitors
MeSH PA D000068760 Serotonin and Noradrenaline Reuptake Inhibitors
MeSH PA D000928 Antidepressive Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D049990 Membrane Transport Modulators
FDA EPC N0000175749 Serotonin and Norepinephrine Reuptake Inhibitor
FDA MoA N0000182137 Cytochrome P450 2D6 Inhibitors
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:35469 antidepressant

Related Drugs by ATC class:

N06AX Other antidepressants 28 drugs
agomelatinebifemelanebrexanolonebupropiondextromethorphanduloxetineesketaminegepironelevomilnacipranmedifoxaminemianserinmilnacipran show all 28 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Major depressive disorder indication 370143000
Generalized anxiety disorder off-label use 21897009 DOID:14320
Social phobia off-label use 25501002 DOID:11257
Menopausal flushing off-label use 198436008
Neuropathic pain off-label use 247398009
Panic disorder off-label use 371631005 DOID:594
Ocular hypertension contraindication 4210003 DOID:9282
Suicidal thoughts contraindication 6471006
Hypercholesterolemia contraindication 13644009
Bipolar disorder contraindication 13746004 DOID:3312
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Hypertensive disorder contraindication 38341003 DOID:10763
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Syndrome of inappropriate vasopressin secretion contraindication 55004003 DOID:3401
Cerebrovascular disease contraindication 62914000 DOID:6713
Blood coagulation disorder contraindication 64779008 DOID:1247
Hyponatremia contraindication 89627008
Seizure disorder contraindication 128613002
Bleeding contraindication 131148009
Impaired renal function disorder contraindication 197663003
Mania contraindication 231494001
Hypomania contraindication 231496004
Interstitial lung disease contraindication 233703007 DOID:3082
Disease of liver contraindication 235856003 DOID:409
Hypertriglyceridemia contraindication 302870006
Serotonin syndrome contraindication 371089000
Angle-closure glaucoma contraindication 392291006 DOID:13550
Myocardial infarction in recovery phase contraindication 418044006
Hypertensive urgency contraindication 443482000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.79 acidic
pKa2 9.33 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 7.33 WOMBAT-PK CHEMBL
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Ki 6.28 WOMBAT-PK CHEMBL
Sodium-dependent dopamine transporter Transporter Ki 5.43 CHEMBL
Alpha-1A adrenergic receptor GPCR IC50 7.22 CHEMBL

External reference:

IDSource
D07793 KEGG_DRUG
4027338 VUID
N0000176142 NUI
386750-22-7 SECONDARY_CAS_RN
4027338 VANDF
C1880288 UMLSCUI
CHEBI:83527 CHEBI
CHEMBL1118 ChEMBL_ID
CHEMBL1201728 ChEMBL_ID
CHEMBL3989861 ChEMBL_ID
DB06700 DRUGBANK_ID
7158 IUPHAR_LIGAND_ID
8361 INN_ID
93414-04-1 SECONDARY_CAS_RN
NG99554ANW UNII
125017 PUBCHEM_CID
683693 RXNORM
132507 MMSL
200628 MMSL
25184 MMSL
339716 MMSL
38906 MMSL
d07113 MMSL
012574 NDDF
012575 NDDF
015249 NDDF
430267008 SNOMEDCT_US
430271006 SNOMEDCT_US
433292007 SNOMEDCT_US
D000069468 MESH_DESCRIPTOR_UI
NG99554ANW INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
PristiqExtended-Release HUMAN PRESCRIPTION DRUG LABEL 1 0008-1210 TABLET, EXTENDED RELEASE 25 mg ORAL NDA 35 sections
PristiqExtended-Release HUMAN PRESCRIPTION DRUG LABEL 1 0008-1210 TABLET, EXTENDED RELEASE 25 mg ORAL NDA 35 sections
PristiqExtended-Release HUMAN PRESCRIPTION DRUG LABEL 1 0008-1211 TABLET, EXTENDED RELEASE 50 mg ORAL NDA 35 sections
PristiqExtended-Release HUMAN PRESCRIPTION DRUG LABEL 1 0008-1211 TABLET, EXTENDED RELEASE 50 mg ORAL NDA 35 sections
PristiqExtended-Release HUMAN PRESCRIPTION DRUG LABEL 1 0008-1222 TABLET, EXTENDED RELEASE 100 mg ORAL NDA 35 sections
PristiqExtended-Release HUMAN PRESCRIPTION DRUG LABEL 1 0008-1222 TABLET, EXTENDED RELEASE 100 mg ORAL NDA 35 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 0054-0400 TABLET, FILM COATED, EXTENDED RELEASE 50 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 0054-0401 TABLET, FILM COATED, EXTENDED RELEASE 100 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 0054-0603 TABLET, FILM COATED, EXTENDED RELEASE 25 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 0591-3659 TABLET, EXTENDED RELEASE 50 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 0591-3660 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 0591-4060 TABLET, EXTENDED RELEASE 25 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 10135-821 TABLET, EXTENDED RELEASE 50 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 10135-822 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 30 sections
Desvenlafaxine Succinate Human Prescription Drug Label 1 33342-388 TABLET, EXTENDED RELEASE 50 mg ORAL ANDA 30 sections
Desvenlafaxine Succinate Human Prescription Drug Label 1 33342-389 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 30 sections
Desvenlafaxine Human Prescription Drug Label 1 35208-009 TABLET, EXTENDED RELEASE 50 mg ORAL ANDA 30 sections
Desvenlafaxine Human Prescription Drug Label 1 35208-010 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 30 sections
Desvenlafaxine Human Prescription Drug Label 1 46708-152 TABLET, EXTENDED RELEASE 50 mg ORAL NDA 30 sections
Desvenlafaxine Human Prescription Drug Label 1 46708-153 TABLET, EXTENDED RELEASE 100 mg ORAL NDA 30 sections
Desvenlafaxine Human Prescription Drug Label 1 46708-540 TABLET, EXTENDED RELEASE 50 mg ORAL ANDA 30 sections
Desvenlafaxine Human Prescription Drug Label 1 46708-541 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 30 sections
Desvenlafaxine Human Prescription Drug Label 1 46708-542 TABLET, EXTENDED RELEASE 25 mg ORAL ANDA 30 sections
Desvenlafaxine Succinate HUMAN PRESCRIPTION DRUG LABEL 1 50090-4069 TABLET, EXTENDED RELEASE 50 mg ORAL NDA AUTHORIZED GENERIC 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 50090-4388 TABLET, EXTENDED RELEASE 25 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 50090-4806 TABLET, FILM COATED, EXTENDED RELEASE 50 mg ORAL ANDA 30 sections
Desvenlafaxine Human Prescription Drug Label 1 50090-5274 TABLET, EXTENDED RELEASE 25 mg ORAL ANDA 30 sections
Desvenlafaxine Human Prescription Drug Label 1 50090-5293 TABLET, EXTENDED RELEASE 50 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 50090-6738 TABLET, EXTENDED RELEASE 25 mg ORAL ANDA 30 sections
Desvenlafaxine Succinate HUMAN PRESCRIPTION DRUG LABEL 1 50090-6894 TABLET, FILM COATED, EXTENDED RELEASE 50 mg ORAL ANDA 24 sections